Integrated Genomic Analyses of Ovarian Carcinoma
Explore this paper's citation graph
Summary
It is reported that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1,BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes.
- Type
- article
- Published
- 2011-06-01
- Cited by
- 7,607
- References
- 68
- Access
- Open access
- OpenAlex
- https://openalex.org/W2123696077
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4321183
Keywords
Ovarian cancer, Biology, microRNA, DNA methylation, Exon
References
- BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
- K‐ras mutations in mucinous ovarian tumors
- Current protocols in human genetics
- Human Protein Reference Database
- Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.
- The emerging roles of forkhead box (Fox) proteins in cancer
- Pro-proliferative FoxM1 is a target of p53-mediated repression
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
- Deletion of Forkhead Box M1 Transcription Factor from Respiratory Epithelial Cells Inhibits Pulmonary Tumorigenesis
- p53 mutation is infrequent in clear cell carcinoma of the ovary.
- The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
- Reply to J. Veeck et al
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
- Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
- Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM)
- Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
- Hybrid selection of discrete genomic intervals on custom-designed microarrays for massively parallel sequencing
- THE CELL OF ORIGIN OF OVARIAN EPITHELIAL TUMORS
- Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer
Cited by
- Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil
- Is molecular diagnostics ready for its cancer close‐up?
- Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
- Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth
- Integrated Analysis Reveals hsa-miR-142 as a Representative of a Lymphocyte-Specific Gene Expression and Methylation Signature
- ZNF385B and VEGFA Are Strongly Differentially Expressed in Serous Ovarian Carcinomas and Correlate with Survival
- Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics
- Predictive Modeling Using a Somatic Mutational Profile in Ovarian High Grade Serous Carcinoma
- Determining the effect of DNA methylation on gene expression in cancer cells.
- High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival
- Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity
- The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles.
- Evidence for the antagonistic form of CXC‐motif chemokine CXCL10 in serous epithelial ovarian tumours
- AKT-independent PI3-K signaling in cancer – emerging role for SGK3
- Inferring tumour purity and stromal and immune cell admixture from expression data
- Tumorgrafts as in vivo surrogates for women with ovarian cancer
- Insights into Wild‐Type and Mutant p53 Functions Provided by Genetically Engineered Mice
- MOLECULAR BIOMARKERS OF RESIDUAL DISEASE AFTER SURGICAL DEBULKING OF HIGH-GRADE SEROUS OVARIAN CANCER
- Proteogenomic convergence for understanding cancer pathways and networks
- In 2014, can we do better than CA125 in the early detection of ovarian cancer?
Related papers
- Characterization of a novel alternatively-spliced 5' exon in the human insulin-like growth factor I (IGF-I) gene, expressed in liver and some cancers.
- Nitric oxide synthase 1 mRNA: tissue-specific variants from rat with alternative first exons.
- The Relative Strengths of SR Protein-mediated Associations of Alternative and Constitutive Exons Can Influence Alternative Splicing*
- Structure of the glucocorticoid receptor (NR3C1) gene 5' untranslated region: identification, and tissue distribution of multiple new human exon 1.
- The Levels of Tau Isoforms Containing Exon-2 and Exon-10 Segments Increased in the Cerebrospinal Fluids of the Patients with Sporadic Creutzfeldt-Jakob Disease
- Methylation of exon 2 of p16 is associated with late stage oesophageal cancer.
- Low-grade serous ovarian carcinoma: an evolution toward targeted therapy
- PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.